p53、C-erbB-2、nm23基因及雌孕激素受体在乳腺癌组织中的表达及其临床意义

目的：观察雌激素受体(ER)、孕激素受体(PR)和p53、C—erbB—2、nm23基因在乳腺癌组织中的表达并探讨其临床意义。方法：应用免疫组化S—P法．对96例乳腺癌组织进行了ER、PR、p53、C—erbB—2、nm23检测，结合临床表现及随访结果作统计学分析。结果：ER、PR、p53、C—erbB-2、nm23阳性表达率分别为52.1％、47．9％、46.9％、62．5％、70.8％。浸润型乳腺癌组织C—erbB-2阳性表达明显高于非浸润型(P＜0．01)；ER、PR 、p53、nm23阳性表达与病理类型无关(P＞0．05)。有淋巴结转移组P53、C—erbB-2的阳性表达率明显高于无淋巴结转移组。有淋巴结转移组nm23的阳性表达率显著低干无淋巴结转移组。差异均有非常显著性(P＜0．01)；而ER、PR的阳性表达率与淋巴结转移与否无关(P＞0．05)。ER和(或)PR、nm23阳性组乳腺癌复发率明显低于阴性组(P＜0．05)，而p53、C—erbB—2阳性组乳腺癌复发率明显高于阴性组(P＜0．05)。结论：检测乳腺癌组织中的ER、PR及p53、C—erbB-2、nm23基因对评价乳腺癌患者的预后有重要价值。

Expression of p53,C-erbB-2 and nm23 genes and estrogen ,progestogen receptors in breast cancer and their clinical significance

Objective:To observe the expression of estrogen receptor(ER),progestogen receptor (PR)and p53,C erbB 2 and nm23 in breast cancer and their clinical significance.Methods:The expression of ER,PR and p53,C erbB 2 and nm23 was observed by S P immunohistochemical method in 96 patients with breast cancer,their clinical and follow up data were also analysed. Results:The positive expression rates of ER,PR and p53,C erbB 2 and nm23 were 52.1%,47.9%,46.9%,62.5% and 70.8%,respectively.Though the expression of C erbB 2 in the infiltration type of breast cancer was much higher than that in the non infiltration type( P <0.01),there was no obvious correlation between the expression of ER,PR,p53 and nm23,and the histological types ( P >0.05).Compared with breast cancer without lymph node metastasis ,the expression of p53 and C erbB 2 was upregulated ( P <0.01)and in contrast that of nm23 was downregulated ( P < 0.01 )in breast cancer with lymph node metastasis .The expression of ER and PR had no relation to lymph node metastasis ( P >0.05).The recurrence rates of the carcinomas with positive expression of ER/PR and nm23 were lower than those with negative expression ( P <0.05);on the contrary,the relapse rates of the carcinomas with positive expression of p53 and C erbB 2 were superior to those with negative expression ( P <0.05).Conclusion:It is most helpful in evaluating the progneosis of patients with breast cancer to observe the expression of ER,PR and p53,C erbB 2 and nm23.